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Pharmacological treatments in ARDS;
a state-of-the-art update
Andrew James Boyle1,2, Rob Mac Sweeney2 and Daniel Francis McAuley1,2*
Abstract
Despite its high incidence and devastating outcomes, acute respiratory distress syndrome (ARDS) has no specific
treatment, with effective therapy currently limited to minimizing potentially harmful ventilation and avoiding a
positive fluid balance. Many pharmacological therapies have been investigated with limited success to date. In this
review article we provide a state-of-the-art update on recent and ongoing trials, as well as reviewing promising
future pharmacological therapies in ARDS.
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Introduction
Despite its high incidence and devastating outcomes
[1,2], acute respiratory distress syndrome (ARDS) has
no specific treatment, with effective therapy currently
limited to minimizing potentially harmful ventilation
and avoiding a positive fluid balance. ARDS is charac-
terized by breakdown of the alveolar-capillary barrier,
leading to flooding of the alveolar space producing
the classical chest radiograph of bilateral pulmonary
infiltrates. This non-cardiogenic pulmonary edema is
associated with impaired oxygenation, as measured by
the PaO2/FiO2 (P/F) ratio, with a lower P/F ratio in-
dicating more severe hypoxia. Acute lung injury (ALI)
is defined as a P/F ratio <300 mmHg (40kPa) and
ARDS is a sub-group defined on the basis of more
severely impaired oxygenation with a P/F ratio <200
mmHg (26.7 kPa).
Since it was first described in 1967 [3], and despite
over 40 years of research, few pharmacological therapies
have emerged for ARDS. We limited the search strategy
for this state-of-the-art update review to recent rando-
mized controlled trials and meta-analyses, as well as a
review of promising potential future pharmacological
therapies in ARDS in an adult setting.
Neuromuscular blockade
Lung protective ventilation can be achieved in the ma-
jority of patients without using neuromuscular blockade
(NMB) [4]; however, initial small studies eliminating
patient effort via skeletal muscle inhibition with NMB
improved patient-ventilator synchrony, as evidenced
by reduced airway pressures and improved chest wall
compliance. Therefore, in the severely hypoxemic ARDS
patient, NMB may permit lower-pressure, lower-tidal vol-
ume ventilation with a consequent reduction in ventilator-
induced lung injury. These beneficial effects led to a
multi-center, randomized, placebo-controlled trial to as-
sess the effect of NMB upon mortality [5] (Table 1). This
showed that infusion with cisatracuriumbesylate within 48
hours of mechanical ventilation in patients with moderate
ARDS improved 90-day survival. However, no difference
was noted between the intervention and placebo groups
until Day 20. The biological mechanism by which NMB
improves late but not early outcome is unclear. While
promising, the protective effect of neuromuscular bloc-
kade needs to be confirmed in a further phase 3 trial.
β-adrenergic agonists
Alveolar edema is a central feature of ARDS, contribu-
ting to limitation of gaseous exchange and ventilatory
failure. Experimental data suggest β-adrenergic agonists
could accelerate alveolar fluid clearance, as well as pro-
vide cytoprotection, increased surfactant secretion and
decreased endothelial permeability.
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Based on the proposed effect upon alveolar fluid
clearance, the β-Agonist Lung Injury Trial (BALTI)
randomized 60 patients to IV salbutamol or placebo
for seven days [6]. In this small, single center study,
salbutamol therapy significantly reduced extravascular
lung water at Day 7 compared with placebo (Table 1).
Subsequently, two large multi-center, randomized pla-
cebo-controlled trials were initiated. The first American
study, ALTA (Albuterol Treatment for Acute Lung
Injury) [7], enrolled 282 patients with ALI, but failed
to demonstrate a difference in ventilator-free days
between those receiving inhaled β-agonist therapy
and those given placebo, and was stopped early as it
breached the futility boundary (Table 1). In the most
severely ill, as defined by the presence of shock at
randomization, length of stay was significantly increased,
suggesting worse outcome in this sub-group.
BALTI-2 was a concurrent UK multi-center stu-
dy investigating intravenous salbutamol in patients
with ARDS, but was terminated early due to excess
Table 1 Characteristics of trials to date
Study title and
abbreviation
Design
(all placebo-
controlled)
Population
of ALI/ARDS
A) Timing
from ALI
onset B) P/F
ratio
Number
recruited
Intervention Primary
outcome
Result
(intervention
vs control)
Mortality
(intervention
vs control)
Neuromuscular Blockade
in Early ARDS [5]
Phase 2 RCT A) 48 hours
B) <150
340 Cisatracuriumbesylate:
15 mg initially, then
37.5 mg per hour for
48 hours
90-day
survival
31.6% vs 40.7%
(P= 0.08)
28-day: 23.7%
vs 33.3%
(P= 0.05)
The β-Agonist Lung Injury
Trial (BALTI) [6]
Phase 1 RCT A) 48 hours
B) <300
40 Intravenous (IV)
salbutamol for seven
days (15 μg kg-1 h-1)
Extravascular
lung water
(EVLW) at
Day 7
9.2 ± 6 vs
13.2 ±3 ml kg-1
(P= 0.04)
28-day: 58%
vs 66%
(P= 0.4)
Randomized, Placebo-
Controlled Clinical Trial of
an Aerosolized β2-Agonist
for Treatment of Acute
Lung Injury (ALTA) [7]
Phase 2 RCT A) 48 hours
B) < 300
282 Inhaled salbutamol
(5 mg) every 4 hours
for 10 days/24 hours
after extubation
Ventilator-free
days (VFD)
Stopped early
14.4 ± 0.9 vs
16.6 ± 0.9
(P= 0.087)
Death before
discharge:
24.3 ± 3.5 vs
18.5 ± 3.4
(P= 0.261)
Effect of Intravenous β-2
Agonist Treatment on
Clinical Outcomes in
Acute Respiratory Distress
Syndrome (BALTI-2) [8]
Phase 2 RCT A) 72 hours
B) <200
326 IV salbutamol for
seven days (15 μg kg-1
(ideal body weight)
h-1)
28-day
mortality
Stopped early
34% vs 23%
(P= 0.03)
Neutrophil Elastase
Inhibition in Acute Lung
Injury (STRIVE) [9]
Phase 3 RCT A) 48 hours
B) <300
492 Sivelestat infusion 1. 28-day
mortality2.
VFD
Stopped early
1 26.6% vs 26%
(P= 0.847)2.
11.4 ±10.27 vs
11.9 ± 10.1
(P= 0.536)
Efficacy and Safety of
Corticosteroids for
Persistent ARDS (LaSRS)
[14]
Phase 2 RCT A) 7 to 28 days
B) P/F <200
180 Moderate-dose IV
methylprednisolone,
for up to 25 days
60-day
mortality
29.2% vs 28.6%
(P= 1.0)
Methylprednisolone
Infusion in Early Severe
ARDS [15]
Phase 1 RCT A) 72 hours
B) <300
91 Low-dose IV
methylprednisolone,
for up to 28 days
Improvement
in Lung Injury
Score by
Day 7
69.8% vs 35.7%
(P= 0.002)
Hospital
survival 76.2%
vs 57.1%
(P= 0.07)
A Randomized Clinical Trial
of Hydroxymethylglutaryl–
Coenzyme A Reductase
Inhibition for Acute Lung
Injury (HARP) [19]
Phase 2 RCT A) 48 hours
B) <300
60 Simvastatin 80 mg
daily, up to 14 days
Reduction in
EVLW indexed
to actual
body weight
13.7 vs 13.4
(P= 0.90)
Improvements
in secondary
outcomes
Hospital
survival: 19
vs 19 (P= 1.0)
Nebulized Heparin is
Associated with Fewer
Days of Mechanical
Ventilation in Critically Ill
Patients: a Randomized
Controlled Trial [21]
Phase 2 RCT Patients
expected to
require
ventilation for
>48 hours, and
within 24 hours
of ventilation
50 Heparin 25,000 units
every 4 to 6 hours, for
up to 14 days
Average daily
P/F ratio
194.2 ± 62.8 vs
187 ± 38.6
mmHg (P= 0.6)
Improvements
in secondary
outcomes
28-day: 20%
vs 16%
(P= 0.7)
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mortality in the group receiving IV salbutamol [8]
(Table 1).
On the basis of these larger trials, β-agonists should be
avoided in patients with ALI. It is hypothesized that β-
agonists may have a harmful cardiac effect, stimulating
tachyarrhythmias and cardiac ischemia, resulting in a
poorer outcome.
Neutrophil elastase inhibitors
Neutrophil elastase (NE) is a serine protease found in neu-
trophil granules and has a range of physiological effects,
including anti-microbial actions and modification of tissue
repair and inflammation. Excessive NE is capable of de-
grading endothelial basement membrane, and has been
implicated in the pathogenesis of ARDS. Following a posi-
tive study in Japan, silvelestat, a neutrophil elastase inhi-
bitor, was investigated in an international randomized,
double-blind, placebo-controlled, multi-center phase III
trial (STRIVE) [9] (Table 1). The study was stopped pre-
maturely due to an increase in 180-day all-cause mortality.
A more recent meta-analysis of eight clinical trials
(including STRIVE) investigating silvelestat has shown it
to have no effect on short-term mortality, and a worse
outcome for 180-day mortality (Risk Ratio (RR) 1.27, CI
1.00 to 1.62) [10].
Corticosteroids
Given their effective anti-inflammatory properties, there
has been extensive interest in the potential role of corti-
costeroids in both the prevention and treatment of
ARDS. Different regimens have been investigated, vary-
ing from short courses of high-dose steroids to pro-
longed courses of lower doses.
High dose corticosteroids do not prevent ARDS in at
risk subjects [11-13]. Therapeutically, both high-dose
and moderate-dose steroids have so far failed to demon-
strate efficacy in ARDS. An ARDSnet randomized,
double-blind trial in 180 patients with ARDS for more
than seven days, showed no effect of prolonged treat-
ment with moderate-dose methylprednisolone compared
to placebo [14] (Table 1). Although patients were libe-
rated from mechanical ventilation earlier, patients re-
ceiving methylprednisolone were more likely to resume
assisted ventilation, which was thought to be secondary
to neuromuscular effects. In addition, initiation of treat-
ment after 14 days of ARDS was associated with a harm-
ful effect, with increased mortality at 60 and 180 days.
However, the role of low-dose corticosteroids in
established ARDS remains uncertain, with one study of
91 patients demonstrating prolonged low-dose methyl-
prednisolone therapy reduces severity of lung injury by
Day 7 of treatment [15] (Table 1).
Despite a systematic review [16] and meta-analysis
[17], the role of steroids in ARDS remains unclear, and
in light of ongoing uncertainty, further trials are both
planned (NCT01731795) and on-going (NCT01284452)
(Table 2). It is also worth highlighting that the studies
included used what are now considered injurious venti-
lation strategies. It remains uncertain if steroids provide
benefit when combined with lung protective (and, there-
fore, less inflammatory) ventilator strategies.
Statins
HMG CoA-reductase inhibitors (statins) have a range of
physiological effects beyond their role in cholesterol re-
duction, including anti-inflammatory actions and endo-
thelial function modulation. Their effect on pulmonary
inflammation was confirmed during a randomized,
double-blind, placebo-controlled pre-clinical study, where
simvastatin demonstrated a variety of anti-inflammatory
effects during an inhaled lipopolysaccharide (LPS) model
of ARDS in healthy volunteers [18].
A small phase II clinical trial in patients with ARDS
(HARP) [19], suggested a potential role for simvastatin
in the treatment of ARDS, with benefit in pulmonary
and non-pulmonary organ dysfunction with no excess
of adverse events in the intervention group (Table 1).
Two larger trials are presently recruiting in the UK
and Ireland (HARP-2 [20]) and in the USA (SAILS,
NCT00979121), investigating simvastatin and rosuvastatin,
respectively. A phase two trial in Oklahoma was recently
terminated due to poor enrollment (NCT01195428).
Heparin
During the inflammatory process of ARDS fibrin is de-
posited throughout the alveolus, both intra- and extra-
vascularly, impairing oxygenation. Experimental data show
that, among other effects, heparin can reduce fibrin de-
position. This led to a small study investigating the effi-
cacy of nebulized heparin in patients at risk for ARDS
[21]. Although there was no significant effect on the P/F
ratio, this study suggested heparin may increase the num-
ber of ventilator-free days (VFD) (Table 1). The results of
this trial have prompted further studies investigating the
long-term impact of nebulized heparin in patients at risk
of ARDS (ACTRN12612000418875) (Table 2).
Aspirin
During ARDS, platelets become activated and play an im-
portant role in disease progression by sequestering within
the lung, forming micro-thrombi and attracting inflamma-
tory cells to injured tissue. The potent anti-platelet effect
of aspirin may offer a therapeutic approach to this patho-
logical process. Observational data associated pre-hospital
anti-platelet use with a reduction in subsequent ARDS
incidence [22]. This finding was repeated in a separate
study, although when propensity to receive aspirin was in-
cluded in the analysis, the effect was lost [23].
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Clinical trials are planned to investigate the effect of
aspirin on reducing inflammation in a human model of
ARDS (ARENA, NCT01659307), while others are on-
going to assess the impact of aspirin in the prevention of
ARDS (LIPS-A, NCT01504867) (Table 2).
Angiotensin converting enzyme inhibitors/angiotensin
receptor blockers
The renin-angiotensin system (RAS) plays an important
role in the pathogenesis of ARDS, with angiotensin
converting enzyme 1 (ACE1) directing a RAS signal to
Table 2 Ongoing/planned clinical trials in ARDS
Study reference
number
Study title and
abbreviation
Design Population
A) Timing
B) P/F ratio
Anticipated
enrollment
Intervention Primary outcome Status
NCT01731795 Efficacy Study of
Dexamethasone
to Treat the Acute
Respiratory Distress
Syndrome
(DEXA-ARDS)
Phase
2/3 RCT
A) 24 hours
from ARDS
onset B) <200
314 Dexamethasone
(20 mg/day for
five days, then
10 mg/day for
five days)
Ventilator-free
days
Not yet
recruiting
NCT01284452 Efficacy of
hydrocortisone in
treatment of severe
sepsis/septic shock
patients with
ALI/ARDS
Phase
2/3 RCT
A) 12 hours
from organ
dysfunction
B) <300
194 Hydrocortisone
50 mg every six
hours for seven
days
28-day all-cause
mortality
Recruiting
ISRCTN88244364 Simvastatin in acute
lung injury (HARP-2)
[20]
Phase
2/3 RCT
A) 48 hours
from ALI onset
B) <300
540 Simvastatin
80 mg daily
Ventilator-free
days
Recruiting
NCT00979121 Statins for Acutely
Injured Lungs from
Sepsis (SAILS)
Phase
3 RCT
A) 48 hours
from ALI onset
B) <300
1000 Rosuvastatin
20 mg daily
Hospital mortality
Day 60
Recruiting
ACTRN12612000418875 Nebulized heparin
for lung injury
Phase
2 RCT
A) Within 24
hours of
mechanical
ventilation in
at-risk patients
B) <300
256 Nebulised
Heparin 25,000
international
units, every six
hours for up to
10 days
Physical function
assessed using
physical function
component of
SF-36 health
survey
Not yet
recruiting
NCT01659307 The effect of Aspirin on
REducing iNflammation
in human in vivo model
of Acute lung injury
(ARENA)
Phase
2 RCT
Healthy, non-
smoking adults,
using an LPS
model of ALI
33 Aspirin 75 mg or
Aspirin 1,200 mg
Bronchalveolar
lavage
intraleukin-8
concentration
Not yet
recruiting
NCT01504867 LIPS-A: Lung Injury
Prevention Study with
Aspirin
Phase
2 RCT
Adults admitted
to hospital via
the emergency
department at
high-risk of
developing ALI
400 Aspirin 325 mg
Day 1, then
81 mg daily
days 2to 7
Development
of ARDS
Recruiting
ISRCTN95690673 Keratinocyte growth
factor in acute lung
injury to reduce
pulmonary dysfunction
(KARE) [28]
Phase 2 RCT A) 48 hours from
ALI onset B) <300
60 Palifermin
60 μg/kg IV
daily for up to
six days
Oxygenation
index at Day 7
Recruiting
ISRCTN27673620 VItamiN D
Replacement to
Prevent Acute Lung
Injury following
OesophagectOmy
(VINDALOO) [34]
Phase
1/2 RCT
Adults
undergoing
planned
transthoracic
esophagectomy
80 Oral Vitamin D
(100,000 IU)
EVLW at end
of procedure
Recruiting
NCT00789685 Safety, tolerability and
preliminary efficacy of
FP-1201 in ALI and
ARDS
Phase
1/2 Non-
randomized
A) 48 hours from
ALI onset B) <300
37 Interferon-β,
increasing dose
over six days
Clinically
significant
treatment
emergent events,
and all-cause
mortality
Completed
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the angiotensin 1 receptor (AT1R), mediating alveolar
vasoconstriction, permeability and fibrosis. A variant of
ACE1, ACE2, diverts a RAS signal to AT2R, which pro-
motes alveolar vasodilation, decreased permeability and
apoptosis, thus opposing the alternative potentially in-
jurious signaling mechanism [24]. Angiotensin receptor
blockers attenuate ventilator-induced lung injury in ani-
mal models [25], and ACE-inhibitor or angiotensin re-
ceptor blocker therapy on discharge were associated
with reduced mortality in acute respiratory failure pa-
tients [26]. Collectively, these data provide encourage-
ment for future clinical trials in this area.
Stem cell therapy
Regenerative medicine is an emerging field, using stem
cells or growth factors to aid the repair of damaged tis-
sue and organs. Stem cells exhibit anti-inflammatory,
immunomodulatory and reparative effects, largely medi-
ated through secreted growth factors, although cell to
cell contact between stem cells and alveoli also mediates
important effects [27].
This prompts questions regarding the optimal delivery
of stem cell therapy, as animal models of ARDS have
shown survival to increase when treatment was delivered
directly to the bronchial tree [28]. In addition, recent
evidence in ex-vivo human lung models of ALI support
the investigation of delivering stem cells directly to the
lung [29]. Clinical trials are awaited in this promising
area.
Growth factors
Keratinocyte growth factor (KGF), an epithelial growth
factor secreted by fibroblasts, has an important role in
lung injury repair [30]. It increases alveolar cellular pro-
liferation in ARDS, particularly of type II alveolar cells,
enhancing repair. KGF may also have a role during the
injurious process, reducing endothelial permeability and
alveolar edema [30], and improving alveolar fluid clea-
rance [31]. Following the completion of a small pre-
clinical trial testing KGF in an LPS-model of ARDS
(ISRCTN98813895), for which results are awaited, a
phase II trial has commenced investigating the efficacy
and safety of intravenous KGF (palifermin) in ARDS [32]
(ISRCTN95690673) (Table 2).
Other potential therapies
Following data showing an immunomodulatory effect of
vitamin D, animal models of ALI demonstrate that intra-
tracheal administration of vitamin D can reduce neu-
trophil recruitment to the lung [33], which has obvious
implications for future therapy in ALI. Vitamin D is cur-
rently being tested in patients at risk of developing ALI
following esophagectomy [34] (Table 2).
Used in the management of multiple sclerosis,
interferon-β (IFN-β) has been shown in vitro and in
animal models of ALI to reduce vascular leakage and
improve capillary endothelial barrier function [35].
IFN-β therapy has been studied in a phase I/II study
in the UK, for which results are awaited (NCT00789685)
(Table 2).
Finally, vascular endothelial growth factor (VEGF), an
important molecule in the control of vascular permea-
bility, has been found to be elevated in patients with
ARDS [36]. The presence of VEGF inhibitors may
prompt future randomized-controlled trials.
Other therapies, including the use of nitric oxide
[37], prostacyclin [38] and surfactant [39], have been
investigated and found to be ineffective. These add-
itional therapies, plus others, are beyond the scope of
this review, but have been covered in recent review
articles [40,41]
Conclusion
Despite many interventions being studied, to date there
has been little success in developing effective pharmaco-
logical therapies for the management of ARDS. However,
given the high associated morbidity and mortality, pres-
sure remains to continue efforts to improve outcomes.
Increasing numbers of pharmacological therapies are be-
ing investigated, and with encouraging pre-clinical and
early clinical results, it is expected that over the coming
years some will develop into useful agents for the pre-
vention and treatment of ARDS.
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